ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Position Raised by Ameriprise Financial Inc.

Ameriprise Financial Inc. grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 14.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 271,805 shares of the specialty pharmaceutical company's stock after purchasing an additional 34,586 shares during the period. Ameriprise Financial Inc. owned approximately 1.29% of ANI Pharmaceuticals worth $15,025,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP lifted its stake in shares of ANI Pharmaceuticals by 4.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock valued at $37,906,000 after purchasing an additional 30,420 shares in the last quarter. Global Alpha Capital Management Ltd. lifted its stake in shares of ANI Pharmaceuticals by 16.4% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock valued at $34,525,000 after purchasing an additional 88,100 shares in the last quarter. William Blair Investment Management LLC lifted its stake in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock valued at $26,826,000 after purchasing an additional 10,440 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock valued at $23,720,000 after purchasing an additional 3,774 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of ANI Pharmaceuticals by 67.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock valued at $17,226,000 after purchasing an additional 125,438 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Meredith Cook sold 400 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at $5,100,914.85. This trade represents a 0.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares of the company's stock, valued at $4,048,711.50. This trade represents a 1.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,681 shares of company stock valued at $408,498. Corporate insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Stock Up 0.9%

ANI Pharmaceuticals stock traded up $0.52 during mid-day trading on Friday, hitting $57.79. The company's stock had a trading volume of 244,161 shares, compared to its average volume of 302,086. The firm's 50 day moving average is $66.49 and its 200 day moving average is $60.80. The company has a market cap of $1.25 billion, a PE ratio of -105.07 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. The firm had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business's revenue for the quarter was up 43.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.82 EPS. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price on the stock. Truist Financial raised their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 target price on the stock. Guggenheim restated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.